In comparison to constitutively active anti-EGFRvIII/EphA2/IL13Rα2 CAR T cells, synNotch-CAR T cells showed greater anti-tumor efficacy without off-tumor toxicity. The gene discussed is EPHA2; the disease is neoplasm.